REGMF (RemeGen Co) PE Ratio without NRI: 88.60 (As of Jul. 07, 2026) — Near Median


REGMF RemeGen Co Ltd REGMF
41 GF Score
Price $12.05
GF Value $27.68
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co PE Ratio without NRI?

RemeGen Co REGMF -6.23% 41 PE Ratio without NRI is 88.60 as of Jul. 07, 2026, which is 6% above its 10-year median of 83.41. GuruFocus rates REGMF with a GF Score™ of 41/100 and a GF Value™ of $27.68 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 266 Biotechnology companies, RemeGen Co ranks worse than 81.95% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-07), RemeGen Co's share price is $12.05. RemeGen Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14. Therefore, RemeGen Co's PE Ratio without NRI for today is 88.60.

During the past 8 years, RemeGen Co's highest PE Ratio without NRI was 113.87. The lowest was 65.05. And the median was 83.41.

RemeGen Co's EPS without NRI for the three months ended in Dec. 2025 was $0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14.

As of today (2026-07-07), RemeGen Co's share price is $12.05. RemeGen Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.30. Therefore, RemeGen Co's PE Ratio (TTM) for today is 39.90.

Warning Sign:

RemeGen Co Ltd stock PE Ratio (=57.37) is close to 1-year high of 57.37.

During the past years, RemeGen Co's highest PE Ratio (TTM) was 51.15. The lowest was 29.22. And the median was 37.47.

RemeGen Co's EPS (Diluted) for the three months ended in Dec. 2025 was $0.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.30.

RemeGen Co's EPS (Basic) for the three months ended in Dec. 2025 was $0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.30.


RemeGen Co  (OTCPK:REGMF) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


RemeGen Co PE Ratio without NRI Related Terms


RemeGen Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for RemeGen Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RemeGen Co PE Ratio without NRI Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial 111.23 At Loss At Loss At Loss 552.69

RemeGen Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 552.69

REGMF vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison

For the Biotechnology subindustry, RemeGen Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RemeGen Co PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where RemeGen Co's PE Ratio without NRI falls into.


REGMF
41GF Score
RemeGen Co Ltd REGMF
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RemeGen Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

RemeGen Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=12.05/0.136
=88.6

RemeGen Co's Share Price of today is $12.05.
RemeGen Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.14.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 88.60 mean?
RemeGen Co (REGMF) has a PE Ratio without NRI of 88.60 as of Jul. 07, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on RemeGen Co and its competitors. This is near median its historical median of 83.41. Over the past decade, RemeGen Co's PE Ratio without NRI has ranged from 65.05 to 113.87. According to the industry distribution chart, RemeGen Co ranks #218 out of 266 companies in the Biotechnology industry, placing it in the top 82%.
Is RemeGen Co's PE Ratio without NRI too high?
RemeGen Co's current PE Ratio without NRI of 88.60 is near median its 10-year median of 83.41. Over the past 10 years, this metric has ranged from a low of 65.05 to a high of 113.87. The Biotechnology industry median PE Ratio without NRI is 25.36. RemeGen Co's value of 88.60 is 249.4% above this industry median. Based on the distribution chart, RemeGen Co ranks #218 out of 266 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, RemeGen Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #218 out of 266 companies for PE Ratio without NRI. This places RemeGen Co in the lower half of its industry. The industry median PE Ratio without NRI is 25.36. RemeGen Co's value of 88.60 is 249.4% above this benchmark. Historically, RemeGen Co's own PE Ratio without NRI has ranged from 65.05 to 113.87 over the past decade. While the company's 10-year median is 83.41 vs. the industry median of 25.36, RemeGen Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.36, based on 266 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current PE Ratio without NRI of 88.60 is 249.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current PE Ratio without NRI is 88.60, which is near median its own 10-year median of 83.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.68, compared to a current price of $12.05 — trading 56.5% below its estimated fair value. The current PE Ratio without NRI is 88.60, which is near median its 10-year median of 83.41 and 249.4% above the Biotechnology industry median of 25.36. RemeGen Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For RemeGen Co (REGMF), the current PE Ratio without NRI is 88.60 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (REGMF) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of $12.05 is trading 56.5% below its estimated GF Value™ of $27.68. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for REGMF:

  • PE Ratio without NRI: 88.60 (near median its 10-year median of 83.41)
  • GF Value™: $27.68 vs. price of $12.05 (56.5% below fair value)
  • GF Score™: 41/100 with 6 warning signs
  • Industry Position: 249.4% above the Biotechnology median (#218 of 266)

No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
41GF Score

Get the complete analysis for REGMF

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price
$27.68
GF Value